Drug intelligence / Profile preview

eltrombopag + ianalumab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy consisting of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), and ianalumab, a fully human immunoglobulin G1 monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R). Eltrombopag works by stimulating thrombopoietin receptors to increase platelet production, while ianalumab has a dual mechanism of action: depleting B cells through antibody-dependent cellular cytotoxicity and inhibiting B-cell functions via BAFF-R blockade. This combination is being investigated for the treatment of primary immune thrombocytopenia (ITP), particularly in patients who have failed first-line steroid treatment.

Brand names: Promacta (eltrombopag)Revolade (eltrombopag)

Targets

TPOR (Thrombopoietin receptor)TNFRSF13C (B-cell Activating Factor Receptor)

Beyond the preview

Go deeper on eltrombopag + ianalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eltrombopag + ianalumab.

Explore the full profile